Vaccine-induced Immunity in Immunocompromised Patients

Recruiting now

Conditions studied: Immunodeficiency

In brief

Managing respiratory virus infections in immunocompromised patients requires a multidisciplinary approach, including vaccination, though its effectiveness is often suboptimal in these individuals. In hematological patients, poor humoral immunogenicity is common, especially when the B cell axis is affected by disease or treatment, while T cell responses may offer better protection. Current immunologic data on these patients is limited, focusing mostly on serologic parameters. To address this, we will conduct an observational study analyzing early and late booster vaccinations, with a focus on virus-specific T cell responses in vaccinated patients.

Key facts

Study ID

NCT06612515

Run by

University of Cologne

People needed

1000

Starts

2025-03-25

Expected to finish

2029-12-31

Last updated by the study team

2026-05-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Signed informed consent form
• Patients with immunosuppression either by treatment or underlying diseases
• Patients who are vaccinated or willing to be vaccinated against respiratory virus infections in ac-cordance with current recommendations
• Age of 18 years or older

You may not qualify if…

• Patients unwilling/ineligible for vaccination under current recommendations

Where it is running

• University Hospital Cologne — Cologne, North Rhine-Westphalia, Germany (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.